Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033516 | 1.00 | SMO (0.49) | SMOSMN1; SMN2GPR119OPRM1OPRD1 | |
| SCHEMBL13033521 | 1.00 | SMO (0.49) | SMOSMN1; SMN2GPR119OPRM1OPRD1 | |
| SCHEMBL1283758 | 0.93 | SMO (0.48) | SMOGPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL1283753 | 0.93 | SMO (0.48) | SMOGPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL13033765 | 0.93 | SMO (0.48) | SMOGPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL13033517 | 0.90 | GPR119 (0.52) | SMOGPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL13033594 | 0.89 | POLB (0.42) | SMN1; SMN2GPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL3512580 | 0.87 | SMO (0.54) | SMOGPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL13033820 | 0.86 | UCHL1 (0.47) | SMOGPR119OPRM1OPRD1OGFRL1 | |
| SCHEMBL13033825 | 0.86 | UCHL1 (0.47) | SMOGPR119OPRM1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | SMO 3/4885SMN1; SMN2 2687/4885GPR119 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.